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Background: The objective of this study was to evaluate the effect on outcomes of intraoperative recombinant
human interleukin-2 injection after surgical resection of peripheral nerve sheath tumours. In this double-blind trial,
40 patients due to undergo surgical excision (<5 mm margins) of presumed peripheral nerve sheath tumours were
randomized to receive intraoperative injection of interleukin-2 or placebo into the wound bed.
Results: There were no significant differences in any variable investigated or in median survival between the two
groups. The median recurrence free interval was 874 days (range 48–2141 days), The recurrence-free interval and
overall survival time were significantly longer in dogs that undergone the primary surgery by a specialist-certified
surgeon compared to a referring veterinarian regardless of whether additional adjunct therapy was given.
Conclusion: Overall, marginal excision of peripheral nerve sheath tumours in dogs resulted in a long survival time,
but adjuvant treatment with recombinant human interleukin-2 (rhIL-2) did not provide a survival advantage.
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Peripheral nerve sheath tumours (PNSTs) are spindle cell
tumours that arise from the connective tissue components
of the peripheral nerve and which can infiltrate the subcu-
tis locally [1]. These tumours are thought to arise from
perineural fibroblasts, which produce the non-myelinated
connective tissues that surround the myelinated nerve
fibre [2-6]. PNSTs appear to be pseudo-encapsulated, are
locally invasive, and grow relatively slowly. Although
PNST rarely metastasize, local recurrence is described
commonly after resection [7-11].
Surgical removal of PNST with margins of minimally
2–3 cm margins in all dimensions is the therapy of
choice. Marginal excision, which is defined as resection
through the tumour pseudocapsule or surrounding re-
active tissue, increases the likelihood of local recurrence
and necessitates re-excision or postoperative radiation
[12]. Since surgical removal alone does not guarantee* Correspondence: a.n.haagsman@uu.nl
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distribution, and reproduction in any mediumcomplete eradication of the tumour, radiotherapy is advo-
cated as adjuvant therapy, and especially when tumours
are marginally or incompletely excised, to prolong survival
and to decrease the incidence of recurrences. Radiother-
apy can also be given preoperatively to decrease the size
of the tumour [7,13]. Chemotherapy has also been used as
adjuvant therapy for canine PNST with mixed results
[7,13-15].
Immunotherapy has become popular in human medi-
cine and decreases the rate of recurrence and metastases
in a variety of tumours, including sarcomas [16-18]. Sys-
temically administered cytokines, such as interleukin-2
(IL-2), activate the immune system to enhance immune-
mediated responses against the tumour, thereby dimin-
ishing its metastatic potential [19]. IL-2 is a T-cell growth
factor and induces clonal expansion of antigen-specific T-
cells and activation of antigen-presenting cells (APC). It
also increases the production of cytokines, such as
interferon- gamma (IFN-γ), tumour necrosis factor alpha
(TNF-α), and interleukin-6 (IL-6), and stimulates natural
(NK) and lymphokine-activated killer cells (LAK) [11]. IL-
2 modulates or promotes major histocompatibility com-
plex (MHC) antigen expression, driving the tumourtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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human IL-2 (rhIL2) is commonly used as adjuvant to
chemotherapy or radiotherapy [16,21], and its intratu-
moural administration has proven beneficial in melanoma
and nasopharyngeal carcinoma, providing a complete re-
sponse rate of 62.5% and a partial response rate of 21%;
the rate of progressive disease was 16.5% [22].
Local rhIL2 therapy (intratumoural, peritumoural, or
intravesical) is suggested to be more effective than
systemic rhIL2 therapy and to have fewer side effects
[17,20,23]. It has proven effective in the treatment of soft
tissue sarcomas (STS) [22,23], malignant lymphoma
[24], and gastrointestinal tumours [25] in humans, mice,
and dogs. Local injection of rhIL2 leads to extravasation
of erythrocytes at the injection site [26], causing stagna-
tion of blood flow and leading to tumour cell death. At a
later stage, leukocytes migrate to the dead tumour cells,
forming a granuloma and causing angiogenesis [20].
Locally applied rhIL2 also decreases the size of distant
metastases by an as yet unknown mechanism [24,26-28].
Local IL-2 therapy has been studied extensively in mice
[29-32]. A study has reported its use in dogs with
confirmed STSs, where treatment consisted of Staphylo-
coccus aureus enterotoxin A and canine interleukin-2
(L_SEA/cIL-2) [33]. The treatment was well tolerated
and had antitumour activity. Other tumours successfully
treated with intratumoural rhIL2 therapy include canine
transmissible venereal tumours [34], bovine ocular squa-
mous cell carcinomas [35], equine sarcoid tumours [36],
and canine mast cell tumours [37].
To the authors’ knowledge, the effect of adjuvant
intralesional rhIL2 after surgical resection has not been
studied in dogs. If rhIL2 has local or systemic effects, it
should decrease the rates of recurrence and distant
spread. The aim of this study was to evaluate the pos-
sible beneficial effect of local rhIL2 administration after
marginal PNST removal in dogs.
Methods
In the period between 2000 and 2003, 40 dogs (any breed,
age, or sex) with a clinical diagnosis of PNST were
referred to two referral practices in the Netherlands
(Department of Clinical Sciences of Companion Animals,
Faculty of Veterinary Medicine, Utrecht University [UU]
and Animal Medical Centre Amsterdam [AMCA]). The
inclusion criterion was presumed PNST that could not be
removed with adequate 3-cm margins. This study in-
cluded 21 dogs without previous surgery and 19 dogs with
previous surgery. All the cases that were presented with
previous surgery had macroscopic recurrences. Dogs with
metastases or multiple tumours were excluded. The
following data were collected: sex, age, weight, PNST
localization (1. phalanges to carpus, 2 carpus to elbow, 3.
elbow to shoulder, 4. cervical region, 5. phalanges totarsus, 6. tarsus to stifle, 7. stifle to hip, 8. flank and 9.
head), fine-needle biopsy and histology findings, location
of metastasis and tumour grade. All dogs were screened
for metastases, using right lateral, left lateral, dorsoventral
or ventrodorsal radiographs of the lungs. A fine-needle as-
piration biopsy (FNAB) was taken from all tumours. All
tumours were removed with margins of 5 mm or less and
submitted for histological examination by a certified path-
ologist (MK) to determine the type and grade of the
tumour and the completeness of resection.
Recombinant human IL-2 (rhIL2; specific activity 18 ×
106 IU/mg; Proleukin® a gift from Chiron, Amsterdam,
the Netherlands) was reconstituted to 1 mg/ml with
distilled water. Polygeline was added to increase the sta-
bility of interleukin. Further dilutions were made with
phosphate-buffered saline (PBS) supplemented with 0.1%
bovine serum albumin, fraction V (BSA; Sigma Chemical
Co., MO USA) [38]. The placebo contained distilled
water with polygeline. Directly after surgical removal of
the tumour, rhIL2 (1 ml containing 4.5 million IU) or
placebo was injected evenly into the wound bed (0.01–
0.05 ml per site) in an at random double-blinded fashion
[20,34]. The wound bed was larger than the tumour by
5 mm in all dimensions and depended on the tension in
that specific area. The exact wound size was not mea-
sured before or after injection. Surgery was performed
by one of two surgeons (BS and JK). None of the patients
received postoperative radiotherapy or chemotherapy.
Blinding was broken after data had been accumulated and
analysed.
Directly after surgery, the wounds were evaluated for
signs of redness, haemorrhage, swelling, tenderness, and
possible wound closure defects. All dogs were routinely
screened for physical signs of regrowth and radiographic
signs of metastasis at 1, 3, 6, and 12 months after
surgery and every 12 months thereafter. If clinical signs
developed before the screening time points, dogs were
examined immediately. Recurrence was confirmed by
evaluation of cytological or histological biopsy speci-
mens. At the end point of the study, either the dog
owner or the referring veterinarian was contacted by
telephone for follow-up and administered a standard
questionnaire including questions about breed, sex, age,
disease-free interval, metastasis occurrence, tumour re-
currence, survival time, and cause of death (if relevant).
The investigators who administered the questionnaires
were blinded to the treatment received.
Overall survival time (OS) was defined as the interval
between the date of surgery and death due to the disease
or the date on which the dog was last known to be alive.
Metastasis free (MFI) and recurrence free (RFI) interval
was defined as the interval between the date of the sur-
gery and the date of either metastases or recurrence, or
if there were no signs of recurrence or metastases, as the
Table 1 Statistical data of dogs with peripheral nerve
sheath tumours receiving recombinant human
interleukin-2 (rhIL2) or a placebo
rhIL2 Placebo Significance
Sex 12 M: 8F 10 M: 10 F NS
Localisation Front leg 10 Front leg 14 NS
Rear leg 6 Rear leg 3
Axial 2 Axial 3
Left vs right L 9: R11 L14: R6 NS
Grade Grade 1: 2 Grade 1: 6 NS
Grade 2: 11 Grade 2: 9
Grade 3: 7 Grade 3: 5
Previous sx yes: no 10:10 yes: no 9:11 NS
Size* 45.6 ± 16.0 19.8 ± 4.0 NS
Age* 9.3 ± 0.55 8.9 ± 0.60 NS
Weight* 33.1 ± 1.7 29.2 ± 2.1 NS
NS No significant difference between the two groups, vs Versus, sx Surgery, M
Male, F Female, L Left, R Right, axial Head or trunk; * described as mean ±
standard error.
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was last known to be alive. Dogs that had died from un-
related causes or which were still alive at the time of
follow-up and without signs of either recurrence or
metastases were considered censored. All dogs had a
follow-up longer than 5 years. If a patient died without
follow-up, the case was classified as lost to follow-up
(LTF) and the last physical and diagnostic examination
was used as end point. If a physical examination was
performed but no diagnostic investigations, only RFI and
OS were recorded; MFI was then coded as LTF. Owners
were asked detailed questions about the surgical site, to
determine whether RFI could be established; if there was
any doubt, the date of the last physical examination was
used in analyses.
Statistical methods
A power analysis was performed in advance of the study,
using survival data obtained from previous studies
[8,11]. With an expected mean RFI difference of 20% per
procedure and a variation coefficient of 15%, an α of
0.05, and a β of 0.15, a total sample size of 40 dogs was
calculated.
Frequency distributions were calculated and categorical
data were compared using Chi-square analysis. Fisher’s
exact test was used when sample sizes were small, i.e. if
more than 25% of the samples were smaller than 5. Nor-
mally distributed, continuous and interval categorical
data were analysed using an analysis of variance
(ANOVA). Logarithmic transformation was performed
on variables that were not normally distributed. A hazard
ratio (HR) of different variables on MFI, RFI, and OS was
calculated using multivariate Cox proportional hazards
analysis. P < 0.05 was considered significant. The Kaplan-
Meier product limit method was used to estimate median
RFI and OS. Group comparisons were made using the
mantel-Cox log rank test (SPSS version 20.0). Statistical
significance was defined as P < 0.05.
Results
Marginal excision (<5 mm) was the only surgical option
for all tumours. The dogs were of different breeds; 4
Beagles, 3 Boxers, 4 Bouviers des Flandres, 2 Bull Ter-
riers, 8 cross breeds, 2 Fox terriers, 3 Bernese Mountain
Dogs, 4 Labrador Retrievers, and one of each following
breeds: English Bulldog, German shorthaired pointer,
Leonberger, Husky, Belgian Shepherd Dog, German
Shepherd Dog, White Shepherd Dog, Groenendaeler,
Flatcoated Retriever, and Irish Wolfhound. Most were
large-breed dogs; the median weight was 31 kg (range
12–51 kg). There were 23 male dogs and 17 female
dogs. The median age of the dogs at referral was 9 years
(range 3–14). Nineteen dogs had previously undergone
tumour resection.Four tumours were located on the forelimb in the area
from the phalanges until the carpus, 15 from the carpus
until the elbow, 7 from the elbow until the shoulder, 5
from the tarsus until the stifle, 4 from the stifle until the
hip, 4 on the head, and 1 on the flank (Table 1). Most tu-
mours were located at the antebrachium (38%) or the
brachium (18%). Fine-needle aspiration biopsies (FNABs)
were used to diagnose 13 mesenchymal proliferations and
15 mesenchymal tumours; the FNABs of 12 dogs were not
diagnostic. There were 29 neurofibrosarcomas, 4 fibrosar-
comas, 2 myxosarcomas, and 5 haemangiopericytomas.
Tumour grade was determined to be low (grade 1) in 8
cases, medium (grade 2) in 20 cases, and high (grade 3) in
12 cases. The median tumour volume was 38.5 cm3 (range
1–2890 cm3). Six dogs developed metastatic disease in the
lungs (5 dogs) and lymph nodes (1 dog). All tumours had
dirty surgical margins (tumour reached or extended into
the surgical margin).
There was no significant difference between the control
group and the IL-2 group in sex, age, weight, tumour
localization, left versus the right side, radiographic appear-
ance of the tumour, results of fine-needle biopsy, location
of metastasis, and tumour grade (Table 1). There were
also no between-group differences after exclusion of dogs
with myxosarcomas and haemangiopericytomas, which
are not classified as true PNSTs. The side effects of ther-
apy were minimal and could not be distinguished from
the normal side effects observed after skin surgery, such
as minor redness, haemorrhage, tenderness of the wound,
and wound swelling. No wound dehiscence was observed.
There was no significant between-group differences in
side effects (data not shown).
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2141 days), the median MFI was 1884 days (range 407–
2141 days) and the median OS was not reached (range
197–2141 days). There was no significant difference in
OS between the treatment groups (Figure 1) or by tumour
group or grade. The rate of recurrence was 45% (9/20) in
the rhIL2 group and 35% (7/20) in the placebo group. Six
dogs developed metastatic disease, 5 in the lungs and 1 in
the lymph nodes; all dogs had previously undergone
surgery. Metastases developed in 3 dogs (15%) that had
received placebo and in 3 dogs that had received rhIL2
and the incidence of metastases did not differ signifi-
cantly between treatment groups. Of the 6 dogs with
metastases, 2 were from grade 1 (n = 8), 3 from grade 2
(n = 20) and 1 from grade 3 tumors (n = 12). There was
no significant difference in incidence of metastases be-
tween the three groups.
The only significant difference in OS (P = 0.006) was
found for dogs that had previously undergone surgery
compared with those that had their first surgery at the
referral clinics (UU or AMCA; Figure 2). Using multi-
variate analysis, the hazard ratio (HR) for recurrence
was higher in dogs that had previously undergone sur-
gery at the time of inclusion compared to dogs that had
not had prior surgery (p < 0.001, HR 10.7, 95% CI 2.3-
21.2; Figure 3). The only other factor that had a signifi-
cant HR was the weight (P = 0.02, HR = 1.08, 95% CI
1.01-1.16). There was no significant difference in occur-
rence of metastases between dogs that had undergone
previous surgery and the ones that had not, using multi-
variate analysis.Figure 1 Kaplan-Meier survival curve of overall survival (OS) showing
with rhIL2 (dotted line) versus placebo (continuous line).Discussion
This study describes the effect on surgical outcomes of
local injection of rhIL2 or placebo into the wound bed
after surgical excision of PNST-like tumours. Treatment
with rhIL2 did not significantly influence the MFI, RFI,
or OS. In contrast, it has been reported to have a benefi-
cial effect in various types of tumours in humans [16,17]
and animals [25,29-31,35,36,39], providing a 6% complete
response (CR) and 10% partial response (PR) in one study
[16] or a 50% decrease in nasal angiosarcoma size in an-
other [17]. In other studies, mice with inoculated lymph-
oma or mastocytoma treated intraperitoneally with IL-2
achieved a 70–90% CR [29-31], cattle with ocular squa-
mous cell carcinoma treated with peritumoural IL-2
achieved a 69% CR [35], and horses with sarcoid tumours
achieved a 14% PR and 43% CR with intratumoural IL-2
[36]. While systemic administration of IL-2 has also been
used, locoregional administration strategies are more ef-
fective and successful [23,26]. Interestingly, local treat-
ment is often effective systemically, eradicating metastases
[32]. Systemic IL-2 therapy can lead to life-threatening
toxicities and to hepatic dysfunction, which might result
in hypotension and vascular fluid accumulation [23].
The use of IL-2 as sole adjuvant agent after sarcoma
resection is not warranted at the moment. Additional
therapies, such as chemotherapy or radiotherapy, may
increase the efficacy of IL-2, but a large effect is unlikely,
especially when a wide surgical excision is used, which
is the preferred approach for PNSTs. In the above-
mentioned study of horses with sarcoid tumours, local
IL-2 treatment combined with chemotherapy (cisplatin)a non-significant difference between dogs with PNSTs treated
Figure 2 Kaplan-Meier survival curve of overall survival (OS) showing a significant difference (P < 0.001) between dogs with PNSTs that
had undergone a previous surgery (dotted line) versus the ones that did not (continuous line).
Figure 3 Kaplan-Meier survival curve of recurrence free interval (RFI) showing a significant difference (p < 0.001) between dogs with
PNSTs that had undergone a previous surgery (dotted line) versus the ones that did not (continuous line).
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apy (53% PR and 80% CR compared with 14% PR and
43% CR, respectively) [36].
Incomplete tumour resection increases patient mor-
bidity, treatment costs, risk of further recurrence, and
ultimately decreases survival time [40-43]. Therefore, the
likelihood of recurrence is much lower if surgery is
performed by a specialist-certified surgeon rather than a
referring veterinarian [13]. We found a much lower recur-
rence rate in dogs that had not previously undergone sur-
gery than in dogs that had previously undergone surgery.
This difference can be explained in two ways: the veteri-
narians who removed the primary tumour might have
used even smaller tumour margins than the specialist-
certified surgeon or the previously removed tumour might
have been more aggressive and more likely to recur. Of
the 40 dogs, 8 had a grade 1 PNST, 20 a grade 2, and 12 a
grade 3. There was no significant difference in grade of
the removed PNST between the dogs with or without pre-
vious surgery. Nor did we find survival or recurrence rates
to differ by tumour grade, but this might be a reflection of
the relatively low number of cases.
The rate of recurrence was similar in the two treat-
ment groups, 45% (9/20; rhIL2 group) versus 35% (7/20;
placebo group). The overall recurrence rate (40%) was
higher than the 15% reported in a comparable study of
41 dogs, in which all dogs that had surgery for re-
currence had been referred after inadequate primary
tumour resection [44]. This difference might be because
we had a longer follow-up of minimally 5 years. Interest-
ingly, tumour recurred at the site of excision many years
after primary surgery, suggesting that dormant cells were
present. This suggests that future studies should have
longer follow-up times (>2 years) and that postoperative
radiotherapy is warranted. Radiotherapy has been used
in many studies after marginal resection of STS, with re-
currence rates varying from 15% to 31%. Irradiated, in-
completely resected STSs had a recurrence rate of 15%
[42] and 17% [43]. However, because these studies did
not investigate PNSTs and did not include rhIL2 ther-
apy, we cannot compare results. Interestingly, a recent
review of human cancer concluded that the response
rate was higher when rhIL2 was used as adjuvant to
radiotherapy [16], an approach that should be evaluated
in the future. Alternative treatment options for incom-
plete tumour resection are re-excision of the wound bed
with wider margins [40,42,44] and downstaging local
disease with preoperative radiotherapy [40].
Most PNSTs in dogs have low metastatic rates. In this
study, 15% of the PNSTs (6/40) had metastasized to
lungs or lymph nodes, and rhIL-2 therapy did not influ-
ence the rate of metastasis. One study of IL-2 used in an
adjuvant setting as local inhalation therapy for carcin-
oma reported that 2 of 7 treated dogs achieved fullremission for more than a year (29%) [45]. Other canine
STS studies have reported lower metastasis rates than
the rate reported here. The rate of metastasis was 8% in
a study in which radiotherapy was used as adjuvant
therapy after incompletely resection [42]. The higher
metastatic rate in our study might have been due to the
longer follow-up, a more vigilant surveying system, or
the presence of dormant cells in the tumour margins.
The results of this study indicate that aggressive primary
surgery is advisable for these tumours.
The higher incidence of metastasis may warrant the
use of postoperative chemotherapy, a protocol not used
in this study. However, the exact role of chemotherapy
in preventing distant metastasis of STS is not known.
Doxorubicin, ifosfamide, and mitoxantrone have been
used in dogs and in humans. The overall response of ca-
nine sarcomas to doxorubicin was 23% in one study
[46], but doxorubicin had no effect as adjuvant therapy
in a recent study of high-grade STS [14]. Cisplatin ap-
plied in a biodegradable implant delivery system directly
after marginal resection of STS in 19 dogs resulted im-
proved survival in 9 dogs (47%) with a median follow-up
of 874 days; 8 dogs died of tumour-unrelated causes,
and 3 dogs had a recurrence (fatal in 1 dog) [47]. Recently,
cyclophosphamide combined with piroxicam significantly
prolonged the DFI of 30 dogs (median DFI >410 days)
compared with that of 55 control dogs (median DFI
211 days) after marginal resection of STSs [43]. The me-
dian OS was not reached in our study, even though follow
up times reached over 5 years. This compares favourable
to other studies reported for surgery alone (1416 days)
[41] or 2270 days after incomplete resection combined
with adjuvant radiotherapy [42] and the 309 days reported
in a study of intraoperative chemotherapy [47] or four-
fraction palliative radiotherapy [48]. Chemotherapy is
typically used in dogs with high-grade and incompletely
resected tumours with a high metastatic rate, which might
explain the high recurrence rate [13].
PNSTs on extremities often cannot be excised with
wide margins and amputation of the limb is a suggested
treatment alternative. However, marginal resection either
as sole therapy or combined with radiotherapy may re-
sult in a similar long-term survival with less immediate
morbidity. Marginal excision of low-grade (G1) STSs
from the extremities of 35 dogs resulted in only 4 recur-
rences (11%) [49]. Similarly, a study showed a grade-
dependent recurrence after marginal excision in 7% (3/
41) of grade 1 (G1) tumours, 34% (14/41) of grade 2 (G2)
tumours, and 75% (3/4) of grade 3 (G3) tumours [41].
Survival time was not influenced by grade in dogs treated
with marginal excision [50]. Radical resection of STSs on
extremities by limb amputation should therefore be con-
sidered as a last resort for recurrent and high-grade tu-
mours, taking into account that the risk of metastases is
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gressive approach, with preoperative incisional biopsies,
seems warranted. Surgical margins can be smaller with
lower grade tumours and still result in positive outcomes.
The study reported here, had longer a follow up and a
grade variation between groups that was identical but the
comparison with historic data prevents any major conclu-
sions when survival outcome is compared to the above-
mentioned studies.
The study had several limitations. Although the entry
criteria were strict and the double-blinded study had a
well-executed follow-up regimen, a major limitation re-
mains the compliance of owners. Unfortunately, owner
compliance is never 100% and some owners lived too far
away to bring their dogs to follow-up evaluations. In
these cases, we consulted the referring veterinarian for
follow-up information, but we have no way of knowing
whether he/she had recently examined the patient. The
variation in tumour size, location, and grade can also
affect outcomes, especially in small case cohorts. In
total, 4.5 million IU of rhIL2 was administered, but the
area of distribution varied with the wound size, which
limits extrapolation of the exact local dose of rhIL2. The
size of the wound should have been measured prior to
injection of rhIL2 or placebo to allow a better calcula-
tion of the exact dose per square cm2. Power analysis
indicated that 40 dogs would be needed to detect a
statistically significant difference between treatments.
However, this is still a small number, especially when
multiple observations and variables are used, such as
the grade and histologic diagnosis. The use of two in-
stead of one referral institute may have influenced the
data although there were no significant differences be-
tween the two institutes for the variables examined
(data not shown).
Conclusion
The long-term prognosis of PNSTs was generally good,
even after marginal resection. Wide resection of these
tumours will most likely result in a better long-term RFI
and OS for more malignant tumours, whereas marginal
excision results in an increased recurrence rate and pos-
sible risk of metastases. This study showed that recur-
rences can occur years after the primary surgery, that
recurrences are much more common after prior sur-
gery, that metastases can occur in both lymph nodes
and lungs, and that intralesional IL-2 does not confer a
survival advantage in dogs with PNSTs. Future studies
should use a stringent follow-up evaluation schedule as
used in this study with minimally a 5-year follow-up to
allow proper analysis of survival statistics. Although
marginal excision of PNST (with or without adjuvant
treatment with rhIL2) resulted in a long survival in a
subset of dogs, presurgical incisional biopsy, wideexcision, and/or adjuvant radiotherapy are advisable to
prevent recurrence and possible metastases.
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